Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]


On page 501, note that in the Results section of the Abstract, the sentence “Trough FEV<sub>1</sub> at week 4 for QVA149 and IND+GLY was 1.46 L ± 0.02 and 1.46 L ± 0.18, respectively.” should read “Trough FEV<sub>1</sub> at week 4 for QVA149 and IND+GLY was 1.5 L ± 0.02.”

On page 505, note that the sentence “The least squares mean ± standard error (LSM ± SE) trough FEV<sub>1</sub> at week 4 for QVA149 and for the free-dose combination of IND+GLY was 1.5 L ± 0.02 and 1.5 L ± 0.18, respectively (Figure 3),” should read “The least squares mean ± standard error (LSM ± SE) trough FEV<sub>1</sub> at week 4 for QVA149 and for the free-dose combination of IND+GLY was 1.5 L ± 0.02 (Figure 3).”

On page 505, note that the confidence interval for Figure 3 was incorrect, and the confidence intervals and y-axis for Figure 4 were also incorrect. The full and correct figures are given here.

Figure 3 Trough FEV<sub>1</sub> (L) at week 4.
Abbreviations: IND+GLY, indacaterol and glycopyrronium; FEV<sub>1</sub>, forced expiratory volume in 1 second; CI, confidence interval.

Figure 4 FEV<sub>1</sub> AUC<sub>0–4h</sub> at day 1 and week 4.
Abbreviations: FEV<sub>1</sub>, forced expiratory volume in 1 second; AUC, area under curve; IND+GLY, indacaterol and glycopyrronium; CI, confidence interval.